AIMS: Whether the selective serotonin re-uptake inhibitor sertraline at 200 mg/day delays relapse in recently abstinent cocaine-dependent individuals. DESIGN: The study involved a 12-week, double-blind, placebo-controlled clinical trial with 2-week residential stay followed by 10-week out-patient participation. SETTING: Veterans Affairs residential unit and out-patient treatment research program. PARTICIPANTS: Cocaine-dependent volunteers (n = 86) with depressive symptoms (Hamilton score > 15), but otherwise no major psychiatric or medical disorder or contraindication tosertraline. MEASUREMENTS: Participants were housed on a drug-free residential unit (weeks 1-2) and randomized to receive sertraline or placebo. Participants then participated on an out-patient basis during weeks 3-12 while continuing to receive study medication. Patients participated in a day substance abuse/day treatment program during weeks 1-3 and underwent weekly cognitive behavioral therapy during weeks 4-12. The primary outcome measure was thrice-weekly urine results and the secondary measure was Hamilton Depression scores. FINDINGS: Pre-hoc analyses were performed on those who participated beyond week 2. Generally, no group differences in retention or baseline characteristics occurred. Sertraline patients showed a trend towards longer time before their first cocaine-positive urine ('lapse', χ(2) = 3.67, P = 0.056), went significantly longer before having two consecutive urine samples positive for cocaine ('relapse', χ(2) = 4.03, P = 0.04) and showed significantly more days to lapse (26.1 ± 16.7 versus 13.2 ± 10.5; Z = 2.89, P = 0.004) and relapse (21.3 ± 10.8 versus 32.3 ± 14.9; Z = 2.25, P = 0.02). Depression scores decreased over time (F = 43.43, P < 0.0001), but did not differ between groups (F = 0.09, P = 0.77). CONCLUSIONS:Sertraline delays time to relapse relative to placebo in cocaine-dependent patients who initially achieve at least 2 weeks of abstinence.
RCT Entities:
AIMS: Whether the selective serotonin re-uptake inhibitor sertraline at 200 mg/day delays relapse in recently abstinent cocaine-dependent individuals. DESIGN: The study involved a 12-week, double-blind, placebo-controlled clinical trial with 2-week residential stay followed by 10-week out-patient participation. SETTING: Veterans Affairs residential unit and out-patient treatment research program. PARTICIPANTS: Cocaine-dependent volunteers (n = 86) with depressive symptoms (Hamilton score > 15), but otherwise no major psychiatric or medical disorder or contraindication to sertraline. MEASUREMENTS: Participants were housed on a drug-free residential unit (weeks 1-2) and randomized to receive sertraline or placebo. Participants then participated on an out-patient basis during weeks 3-12 while continuing to receive study medication. Patients participated in a day substance abuse/day treatment program during weeks 1-3 and underwent weekly cognitive behavioral therapy during weeks 4-12. The primary outcome measure was thrice-weekly urine results and the secondary measure was Hamilton Depression scores. FINDINGS: Pre-hoc analyses were performed on those who participated beyond week 2. Generally, no group differences in retention or baseline characteristics occurred. Sertralinepatients showed a trend towards longer time before their first cocaine-positive urine ('lapse', χ(2) = 3.67, P = 0.056), went significantly longer before having two consecutive urine samples positive for cocaine ('relapse', χ(2) = 4.03, P = 0.04) and showed significantly more days to lapse (26.1 ± 16.7 versus 13.2 ± 10.5; Z = 2.89, P = 0.004) and relapse (21.3 ± 10.8 versus 32.3 ± 14.9; Z = 2.25, P = 0.02). Depression scores decreased over time (F = 43.43, P < 0.0001), but did not differ between groups (F = 0.09, P = 0.77). CONCLUSIONS:Sertraline delays time to relapse relative to placebo in cocaine-dependent patients who initially achieve at least 2 weeks of abstinence.
Authors: Brenda M Booth; Jim Edward Weber; Maureen A Walton; Rebecca M Cunningham; Lynn Massey; Carol R Thrush; Ronald F Maio Journal: Acad Emerg Med Date: 2005-04 Impact factor: 3.451
Authors: E V Nunes; F M Quitkin; S J Donovan; D Deliyannides; K Ocepek-Welikson; T Koenig; R Brady; P J McGrath; G Woody Journal: Arch Gen Psychiatry Date: 1998-02
Authors: Eileen K Sawyer; Jiyoung Mun; Jonathon A Nye; Heather L Kimmel; Ronald J Voll; Jeffrey S Stehouwer; Kenner C Rice; Mark M Goodman; Leonard L Howell Journal: Neuropsychopharmacology Date: 2012-03-21 Impact factor: 7.853
Authors: Christopher D Verrico; Colin N Haile; James J Mahoney; Daisy G Y Thompson-Lake; Thomas F Newton; Richard De La Garza Journal: Drug Alcohol Depend Date: 2014-05-28 Impact factor: 4.492
Authors: David J Grelotti; Gwendolyn P Hammer; James W Dilley; Dan H Karasic; James L Sorensen; David R Bangsberg; Alexander C Tsai Journal: AIDS Care Date: 2016-09-02
Authors: Michael J Mancino; Janette McGaugh; Mohit P Chopra; Joseph B Guise; Christopher Cargile; D Keith Williams; Jeff Thostenson; Thomas R Kosten; Nichole Sanders; Alison Oliveto Journal: J Clin Psychopharmacol Date: 2014-04 Impact factor: 3.153
Authors: Maryam Bashiri; Michael J Mancino; Virginia A Stanick; Jeff Thostenson; Thomas R Kosten; Alison H Oliveto Journal: Am J Addict Date: 2017-11-08
Authors: Diana Martinez; Mark Slifstein; Nabeel Nabulsi; Alexander Grassetti; Nina B L Urban; Audrey Perez; Fei Liu; Shu-Fei Lin; Jim Ropchan; Xiangling Mao; Lawrence S Kegeles; Dikoma C Shungu; Richard E Carson; Yiyun Huang Journal: Biol Psychiatry Date: 2013-09-12 Impact factor: 13.382
Authors: Francisco J Flores-Ramirez; Israel Garcia-Carachure; David O Sanchez; Celene Gonzalez; Samuel A Castillo; Miguel A Arenivar; Anapaula Themann; Omar Lira; Minerva Rodriguez; Joshua Preciado-Piña; Sergio D Iñiguez Journal: J Psychopharmacol Date: 2018-10-18 Impact factor: 4.153